Clinical Trial Finder

• -

  INCLUSION CRITERIA:

  - Inclusion criteria are same in both Phase I and Phase II parts, except for the number of prior disease relapses.

• - Patients must have pathologic diagnosis of anaplastic astrocytoma defined as World Health Organization (WHO) grade III or glioblastoma/gliosarcoma, WHO grade IV, which are confirmed by National Cancer Institute (NCI) Laboratory of Pathology.

If the pathology diagnosis is anaplastic glioma or anaplastic oligoastrocytoma, evidence of either intact combined loss of the short arm chromosome 1 (i.e. 1p) and the long arm of chromosome 19 (1p/19q) chromosomes or molecular features suggesting astrocytic tumor must be present (including, but not limited to alpha-thalassemia/mental retardation, alpha-thalassemia/mental retardation, X-linked (ATRX), tumor protein P53 (TP53).

• - Patients must have recurrent disease, histologically proven or imaging suggestive of recurrent disease as determined by principal investigator (PI).

Prior implantation of Gliadel wafers is acceptable, if tumor recurrence is confirmed by histologic examination of the recurrent tumor.

• - Patients must have the ability to understand and the willingness to sign a written informed consent document.

• - Patients must be greater than or equal to 18 years old.

• - No more than two prior disease relapses to be eligible for the phase I portion of the study and no more than one prior relapse to be eligible for phase II.

• - Patients must have undergone prior standard therapy for their primary disease.

For patients with glioblastoma, this would include surgical resection, or biopsy, if safe resection was not permitted due to the tumor location, radiation and adjuvant temozolomide. For patients with anaplastic astrocytoma, this would include surgical resection, radiation and adjuvant chemotherapy procarbazine, lomustine (CCNU) and vincristine (PCV) or temozolomide.

• - Tumor tissue must be available for review to confirm histological diagnosis.

• - Tumor block or unstained slides must be available for molecular profiling.

• - Karnofsky > 60 percent.

• - Patients must have adequate bone marrow function (absolute neutrophil count (ANC) > 1,500/mm^3, platelet count of > 100,000/mm^3), adequate liver function (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)< 3 times upper limit normal and alkaline phosphatase < 2 times upper limit normal, total bilirubin < 1.5mg/dl), and adequate renal function (blood urea nitrogen (BUN) < 1.5 times institutional normal and serum creatinine < 1.5 mg/dl) prior to registration.

These tests must be performed within 14 days prior to registration. Total bilirubin: patients with Gilbert's Syndrome are eligible for the study. (Total bilirubin level can be exempted from the eligibility criterion.)

• - Patients must have recovered from the toxic effects of prior therapy to less than grade 2 toxicity per Common Terminology Criteria (CTC) version 4 (except deep vein thrombosis) - At the time of registration, subject must be removed from prior therapy as follows: - greater than or equal to (28 days) from any investigational agent, - greater than or equal to 4 weeks (28 days) from prior cytotoxic therapy, - greater than or equal to 2 weeks (14 days) from vincristine, - greater than or equal to 6 weeks (42 days) from nitrosoureas, - greater than or equal to 3 weeks (21 days) from procarbazine administration, - greater than or equal to 1 week (7 days) for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. radiosensitizer does not count.

• - Patients having undergone recent resection of recurrent or progressive tumor will be eligible given all of the following conditions apply: - At least 2 weeks (14 days) have elapsed from the date of surgery and the patients have recovered from the effects of surgery.

• - Evaluable or measureable disease following resection of recurrent malignant glioma is not mandated for eligibility into the study.

• - To best assess the extent of residual disease post-operatively, an magnetic resonance imaging (MRI) should be done no later than 96 hours in the immediate post-operative period or at least within 4 weeks post- operatively, within 14 days prior to registration.

If the 96-hour scan is more than 14 days before registration, the scan needs to be repeated. The patient must have been on a stable steroid dose for at least 5 days prior to the baseline MRI. Steroids may be initiated as clinically indicated once baseline imaging has been completed with a goal of titrating steroids as soon as clinically warranted.

• - Patients must have received prior radiation therapy and must have an interval of greater than or equal to 12 weeks (84 days) from the completion of radiation therapy to study entry except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission tomography (PET) scan) in which case the principal investigators discretion may determine appropriate timepoint at which study therapy may begin.

• - Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration.

The effects of Zotiraciclib (TG02) on the developing human fetus are unknown. For this reason, women of childbearing potential must not be pregnant, must not be breast-feeding, and must practice adequate contraception for the duration of the study, and for 30 days after the last dose of study medication.

• - Male patients on treatment with Zotiraciclib (TG02) must agree to use an adequate method of contraception for the duration of the study, and for 30 days after the last dose of study medication as the effects of Zotiraciclib (TG02) on the developing human fetus are unknown.

• - Patients must agree to enroll on the Neuro-oncology Branch (NOB) Natural History protocol to allow the assessment of molecular tumor markers.

EXCLUSION CRITERIA:

• - Patients who are receiving any other investigational agents.

However, prior enrollment on a study using investigational agents is acceptable.

• - Patients with prior bevacizumab use for tumor treatment.

Patients who received bevacizumab for symptom management, including but not limited to cerebral edema, pseudoprogression can be included in the study (To date, there have been no effective regimens developed for recurrent malignant gliomas that are refractory to bevacizumab. Inclusion of this patient population may impact the ability to determine the efficacy of Zotiraciclib (TG02) with Temozolomide (TMZ.)

• - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from providing informed consent.

• - Any condition, including the presence of clinically significant laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

These would include:

• - Active infection (including persistent fever) including known history of human immunodeficiency virus (HIV) or Hepatitis C infection, because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

• - Diseases or conditions that obscure toxicity or dangerously alter drug metabolism.

• - Serious concurrent medical illness e.g. symptomatic congestive heart failure.

• - History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide and/or Zotiraciclib (TG02).

• - Patients with a history of any other cancer (except non-melanoma skin cancer or melanoma in-situ following curative surgical resection; or carcinoma in-situ of the cervix or bladder), unless in complete remission and off all therapy for that disease for a minimum of 3 years, are ineligible.

• - Zotiraciclib (TG02) is primarily metabolized by Cytochrome P450 1A2 (CYP1A2) and Cytochrome P450 3A4 (CYP3A4).

Patients receiving any medications or substances that are strong inhibitors or inducers of CYP1A2 and/or CYP3A4 are ineligible.

• - Patients, who continue to have prolonged corrected QT interval (QTc) (males: greater than 450ms; females: greater than 470ms as calculated by Fridericia s correction formula) despite normal electrolyte balance and discontinuation of medications known to prolong QTc, will be excluded from the study.

Background:

• - Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3).

It is orally administered and penetrates blood brain barrier (BBB). There is clinical experience in using Zotiraciclib (TG02) as both a single agent and in combination with other chemotherapy agents for cancer treatment.

• - Temozolomide (TMZ) is an oral alkylating agent that has proven efficacy in anaplastic glioma and glioblastoma.

It was approved by the United States (U.S.) Food and Drug Administration (FDA) to treat anaplastic astrocytoma and glioblastoma in adults. Both a dose-dense (dd) schedule, 7 days on and 7 days off and a metronomic (mn) daily dosing schedule have been used to treat recurrent high-grade gliomas.

• - Our preclinical data have demonstrated that Zotiraciclib (TG02) down-regulates cyclin-dependent kinase 9 (CDK9) activity and its target proteins, such as anti-apoptotic protein myeloid-cell leukemia (Mcl-1), X-linked inhibitor of apoptosis (XIAP) and survivin.

A treatment with Zotiraciclib (TG02) and TMZ has synergistic anti-glioma effects in a variety of glioma models with different genetic background. This serves as the basis for this proposed clinical trial. Objectives: Phase I: -To determine the maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma. To select the treatment regimen with better progression free survival (PFS)4 between Zotiraciclib (TG02) plus dd TMZ or mn TMZ at each of the MTDs following cohort expansion. Phase II: -To determine the efficacy of Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent World Health Organization (WHO) grade III or IV astrocytoma as determined by progression free survival. Eligibility:

• - Documented pathology diagnosis of anaplastic astrocytoma [WHO grade III], or glioblastoma/gliosarcoma (WHO grade IV) with recurrent disease.

If the pathology diagnosis is anaplastic glioma or anaplastic oligoastrocytoma, evidence of either intact 1p/19q chromosomes or molecular features suggesting astrocytic tumor must be present. (including, but not limited to α-thalassemia mental retardation X-linked (ATRX) and/or tumor protein P53 (TP53) mutation)

• - No prior use of bevacizumab as a treatment for brain tumor.

• - No more than two prior relapses for Phase I and no more than one prior relapse for Phase II.

• - Patients must have recurrent disease, either histologically proven or with imaging suggestive of recurrent disease.

• - Tumor tissues available for review to confirm the histologic diagnosis.

• - Tumor tissue blocks available for molecular profiling analysis.

Design:

• - Phase I: - This portion of the study is conducted in two stages: The MTD finding and cohort extension.

Two treatment arms and several dose levels are planned.

• - In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered.

• - A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II.

• - Pharmacokinetic, pharmacogenetic studies and neutrophil analysis will be performed during the cohort extension of both arms.

• - A maximum of 72 patients will be enrolled to this component for the trial.

• - Phase II: --Patients will be randomized between two competing treatment arms: ("winner" of dd vs.#46; mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.

The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.

• - The treatment schedule will be identical to that described above in the phase I component, with each cycle comprising 28 days.

• - Patients will continue treatment until tumor progression or unacceptable toxicity occurs.

• - At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).

Arms

Experimental: Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)

dose dense (dd) Temozolomide (TMZ) 125 mg/m^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation

Experimental: Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)

metronomic Temozolomide (TMZ) 50 mg/ m^2 daily plus Zotiraciclib (TG02) dose escalation

Experimental: Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)

Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and "winner" of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I

Active Comparator: Phase II Arm 2 Metronomic Temozolomide (TMZ)

"winner" of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone

Interventions

Drug: - Zotiraciclib (TG02)

Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; --A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.

Drug: - Temozolomide (TMZ)

Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: ("winner" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.